News Enbrel unlikely to face Novartis rival until 2018 Amgen arguing that US patent will last until 2029.
News J&J to "price responsibly", says CEO post Trump meeting Gorsky promises "transparency report" on pricing.
News As rituximab biosimilars close in, Roche showcases Gazyva su... Roche faces competition against its blockbuster haematology drug
News How will Trump presidency affect biosimilars in US? Trump makes vague promise to "reform" FDA - but how?
News Teva buys US rights to Celltrion biosimilars Israeli firm buys rights to near-copies of Roche blockbusters.
News Samsung Bioepis files Herceptin biosimilar in EU South Korean firm trying to copy breast cancer blockbuster.
News Lily gets FDA nod for SERD-CDK 4/6 combo in breast cancer Eli Lilly's imlunestrant (Inluriyo) for breast cancer has received a new FDA approval, in combination with CDK4/6 inhibitor abemaciclib (Verzenio).
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
